S&E Bio
Seoul, South Korea · Founded 2019
- Headquarters
- Seoul
- Employees
- 1–10
- Founded
- 2019
- Business Model
- B2B
- Website
- snebio.com
- Last Round
- Series ADec 2022
- Rounds
- 1
About
S&E bio is a South Korean biopharmaceutical company founded in 2019 by Professor Oh Young Bang of Samsung Medical Center, focused on developing cell-free stem cell therapeutics using mesenchymal stem cell-derived extracellular vesicles (exosomes). The company's lead candidate, SNE-101, received Korea's first MFDS approval in 2025 to begin a Phase 1b clinical trial for exosome-based stroke therapy. S&E bio uses a proprietary 3D culture system to optimize exosome production, with patents granted across Korea, the United States, Europe, and Japan covering its manufacturing methods and therapeutic compositions.
Summary
S&E Bio is a Biotech company based in Seoul, South Korea, founded in 2019. Its most recent funding was a Series A round in Dec 2022. Investors include KB Investment, Korea Investment Partners and Company K Partners.
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2022
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company